Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   95004 News 


«12...313314315316317318319320321322323...10671068»
  • ||||||||||  Dupixent (dupilumab) / Sanofi, Regeneron
    Real-world retrospective analysis of the efficacy of dupilumab in a series of Greek patients with severe atopic dermatitis () -  May 24, 2022 - Abstract #EAACI2022EAACI_2067;    
    Method In this real-world retrospective analysis in the clinical practice setting, 4 adult patients were included, with severe atopic dermatitis and poor response to treatment with topical corticosteroids, tacrolimus, pimecrolimus and cyclosporine (2mg/kg with a max dosage of 5mg/kg) for at least 4 consecutive weeks...Concerning the side effects of the drug, only one patient presented with conjunctivitis in both eyes after the first 2 injections, he was treated with dexamethasone+chloramphenicol drops for at least 7 days and the symptoms subsided and continued his treatment with dupilumab...Conclusion Dupilumab showed excellent therapeutic efficacy with a tolerable safety profile. Even though the series are small in number, all patients showed remarkable improvement in their burden of disease from the very first injections and this reached a peak at week 12 of treatment.
  • ||||||||||  dexamethasone / Generic mfg.
    Tiotropium bromide inhibits mucin hypersecretion and airway inflammation in differentiated airway epithelial cells () -  May 24, 2022 - Abstract #EAACI2022EAACI_2057;    
    Pre-treatment with tiotropium bromide inhibits cold-induced MUC5AC gene expression and protein release, the degree of which was comparable with dexamethasone...Tiotropium decreased phosphorylation of cold-enhanced ERK 1/2 and Jnk MAPK. Conclusion These data show that tiotropium bromide exerts inhibitory effects on cold-induced epithelial mucin production through ERK 1/2 and Jnk MAPK pathways and accompanying airway inflammation, thus providing insight into the underlying mechanisms of clinical benefit of using tiotropium in the treatment of asthma and COPD.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Majie Cataplasm Promotes Th1 Response to Fight against Asthmatic Th2 Inflammation through NKs. (Pubmed Central) -  May 24, 2022   
    Both the dexamethasone and Majie cataplasm could control the asthmatic inflammation by reducing the inflammatory factors, inhibiting the adaptive inflammation reaction in the latter stage of inflammation and furtherly reversing the inhibition of ILC2s, ILC2s, and ILC3s. In addition, Majie cataplasm can promote the quantity of NKs and the content of IL-1α and IFN-γ, induce IFN-γ NKs to shut down the Th2 response, and tend to elicit the Th1 response.
  • ||||||||||  dexamethasone injection / Generic mfg.
    Enrollment open:  A Prospective Pilot Study of a Non-Narcotic Post-Operative Course After Colectomy (clinicaltrials.gov) -  May 24, 2022   
    P4,  N=25, Recruiting, 
    In addition, Majie cataplasm can promote the quantity of NKs and the content of IL-1α and IFN-γ, induce IFN-γ NKs to shut down the Th2 response, and tend to elicit the Th1 response. Not yet recruiting --> Recruiting
  • ||||||||||  dexamethasone / Generic mfg.
    Review, Journal:  Functional Impact of Risk Gene Variants on the Autoimmune Responses in Type 1 Diabetes. (Pubmed Central) -  May 24, 2022   
    We also observed epigenetic and genetic modulation of several of these T1D susceptibility genes in dendritic cells (DCs) treated with vitamin D3 and dexamethasone to acquire tolerogenic properties as compared to immune activating DCs (mDC) illustrating the interaction between genes and environment that collectively determines risk for T1D. A notion that targeting such genes for therapeutic modulation could be compatible with correction of the impaired immune response, inspired us to review the current knowledge on the immune-related minor risk genes, their expression and function in immune cells, and how they may contribute to activation of autoreactive T cells, Treg function or β-cell apoptosis, thus contributing to development of the autoimmune disease.
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    A CASE OF SEVERE ANCA ASSOCIATED VASCULITIS AFTER COVID-19 VACCINATION () -  May 24, 2022 - Abstract #EULAR2022EULAR_4448;    
    Diagnosis of AAV is often delayed or missed by other medical specialties due to its varied presentation. AAV should be suspected in a patient with paraesthesia/weakness in keeping with mononeuritis multiplex or other peripheral neuropathy in the absence of an alternative explanation (e.g. diabetes,B12 deficiency) and in particular with a wrist or foot drop.Exposure to certain drugs and substances of abuse such as cocaine, hydralazine and propylthiouracil has been implicated with AAV.While short-term side effects of COVID-19 vaccine resemble those of other vaccines, long-term side effects remain unknown[2].
  • ||||||||||  SLE ONSET POST COVID-19 VACCINATION: COINCIDENTAL OR ASSOCIATION? () -  May 24, 2022 - Abstract #EULAR2022EULAR_4443;    
    Whether Covid-19 vaccination direct contribute to the occurrence of SLE remained inconclusive. More studies are required to show its correlation between onset of SLE and Covid-19 vaccination.
  • ||||||||||  prednisolone / Generic mfg.
    INFLAMMATORY MYOSITIS – FINAL ANSWER? () -  May 24, 2022 - Abstract #EULAR2022EULAR_4442;    
    On review of her clinical progress, we noted poor response to steroids and EMG results pointing at an alternative diagnosis of MND. This case highlights the importance of EMG in the assessment and management of patients with suspected inflammatory myositis as well as the need to closely monitor progress and re-evaluation where needed.
  • ||||||||||  DIFFERENCES IN THE CLINICAL SPECTRUM OF HAPLOINSUFFICIENCY OF A20 (HA20) CASES DIAGNOSED DURING ADULTHOOD () -  May 24, 2022 - Abstract #EULAR2022EULAR_4232;    
    HA20 can be diagnosed even in adult patients, and the clinical picture of presented cases suggests that monogenic autoinflammatory disorders including HA20 should be suspected in any patient with flares of described manifestations along with strong acute phase response even in adults. Response to corticosteroids and targeted treatments may also be variable.
  • ||||||||||  PROTOCOL VIOLATIONS IN AN OPEN, RANDOMIZED, TRIAL IN EARLY RA PATIENTS: POTENTIAL IMPACT OF SHARED DECISION MAKING () -  May 24, 2022 - Abstract #EULAR2022EULAR_3130;    
    The high frequency is most likely related to the open design of the trial, the risk of adverse effects through intensification with high dose prednisolone and other DMARDs, the randomization phase, and, last but not least, by the shared decision making. Shared decision making by physician and patient may jeopardizes protocol adherence in trials with an open treat-to-target design.
  • ||||||||||  dexamethasone / Generic mfg.
    Enrollment change, Trial initiation date, Trial withdrawal:  Multi-Strategy Intervention for Anesthesia Care of Obese Patients A Factorial Randomized Controlled Trial (clinicaltrials.gov) -  May 23, 2022   
    P=N/A,  N=0, Withdrawn, 
    In silico results can guide scientists and clinicians regarding important physiological and chemical factors that modulate tissue drug concentrations from drug-eluting IOLs. N=180 --> 0 | Initiation date: Sep 2021 --> May 2022 | Recruiting --> Withdrawn
  • ||||||||||  miricorilant (CORT118335) / Corcept Therap
    Enrollment closed:  Medication Development for Protracted Abstinence in Alcoholism: CORT118335 Versus Placebo (clinicaltrials.gov) -  May 23, 2022   
    P2,  N=50, Active, not recruiting, 
    Trial completion date: Jun 2023 --> Mar 2024 | Initiation date: Mar 2022 --> Jan 2023 | Trial primary completion date: Apr 2023 --> Jan 2024 Recruiting --> Active, not recruiting
  • ||||||||||  dexamethasone injection / Generic mfg.
    Trial completion:  Dexamethasone in Pain Control After Total Knee Replacement (clinicaltrials.gov) -  May 23, 2022   
    P4,  N=138, Completed, 
    Trial completion date: Dec 2021 --> Dec 2022 Recruiting --> Completed
  • ||||||||||  carboplatin / Generic mfg.
    Patient-related risk factors for nausea and vomiting with standard antiemetics in patients with receiving carboplatin based chemotherapy (Livestream Metropolitan East, CC, 2nd Floor) -  May 22, 2022 - Abstract #MASCCISOO2022MASCC_ISOO_283;    
    Multivariable logistic regression analysis revealed that age under 70 years and total dexamethasone dose under 14.6 mg were significantly associated with the CR in the overall phase (age: adjusted OR, 1.81 95% CI, 1.02–2.23; P = 0.04; total dexamethasone dose: adjusted OR, 2.58; 95% CI, 1.41–4.71; P = 0.002). Conclusions The findings suggest that age < 70 years and total dexamethasone dose of <14.6 mg might be patient-related risk factors for carboplatin induced CINV.
  • ||||||||||  dexamethasone / Generic mfg., carboplatin / Generic mfg., olanzapine / Generic mfg.
    EFFICACY OF ADDING NK1RA TO 5 MG OLANZAPINE, 5HT3RA, AND DEXAMETHASONE FOR CARBOPLATIN-INDUCED NAUSEA AND VOMITING (Livestream Metropolitan East, CC, 2nd Floor) -  May 22, 2022 - Abstract #MASCCISOO2022MASCC_ISOO_282;    
    Efficacy results are summarized in the Table. Conclusions The findings suggest that 3-drug antiemetic regimens containing 5 mg olanzapine without NK1RA could be an effective standard treatment for patients treated with carboplatin-based chemotherapy.